Wang J 2007.

Methods	Country: China Setting: hospital based Aim: to study the effects of Qianggu capsule in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T‐test, Ridit test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 54 postmenopausal osteoporosis patients enrolled: 28 in trial group, 26 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease‐affected bone metabolism
Interventions	Experimental: Qianggu capsule, 0.25 g, 3 times a day, for 6 months Control: alfa calcidiol capsule, 0.5 μg, twice a day, for 6 months
Outcomes	BMD, Ca, P, ALP, adverse effects
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias